메뉴 건너뛰기




Volumn 25, Issue , 2014, Pages iii83-iii92

Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; METHOTREXATE; MITOXANTRONE; OBINUTUZUMAB; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VENETOCLAX; VINCRISTINE;

EID: 84911469440     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu264     Document Type: Article
Times cited : (127)

References (65)
  • 2
    • 28844449677 scopus 로고    scopus 로고
    • Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
    • Fu K, Weisenburger DD, Greiner TC et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315-4321.
    • (2005) Blood , vol.106 , pp. 4315-4321
    • Fu, K.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 3
    • 84881237232 scopus 로고    scopus 로고
    • European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
    • Cheah CY, George A, Giné E et al. European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24: 2119-2123.
    • (2013) Ann Oncol , vol.24 , pp. 2119-2123
    • Cheah, C.Y.1    George, A.2    Giné, E.3
  • 4
    • 38349104577 scopus 로고    scopus 로고
    • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    • Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
    • (2008) Blood , vol.111 , pp. 558-565
    • Hoster, E.1    Dreyling, M.2    Klapper, W.3
  • 5
    • 77950398416 scopus 로고    scopus 로고
    • Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network
    • Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009; 2: 103-111.
    • (2009) J Hematop , vol.2 , pp. 103-111
    • Klapper, W.1    Hoster, E.2    Determann, O.3
  • 6
    • 76749118059 scopus 로고    scopus 로고
    • Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
    • Fernàndez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
    • (2010) Cancer Res , vol.70 , pp. 1408-1418
    • Fernàndez, V.1    Salamero, O.2    Espinet, B.3
  • 7
    • 84860830052 scopus 로고    scopus 로고
    • Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
    • Nygren L, Baumgartner Wennerholm S, Klimkowska M et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119: 4215-4223.
    • (2012) Blood , vol.119 , pp. 4215-4223
    • Nygren, L.1    Baumgartner Wennerholm, S.2    Klimkowska, M.3
  • 8
    • 84946232805 scopus 로고    scopus 로고
    • Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches
    • Dreyling M; European Mantle Cell Lymphoma Network. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book 2014; 34: 191-198.
    • (2014) Am Soc Clin Oncol Educ Book , vol.34 , pp. 191-198
    • Dreyling, M.1
  • 9
    • 84862194194 scopus 로고    scopus 로고
    • Outcome of deferred initial therapy in mantle-cell lymphoma
    • Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
    • (2009) J Clin Oncol , vol.27 , pp. 1209-1213
    • Martin, P.1    Chadburn, A.2    Christos, P.3
  • 11
    • 84911467224 scopus 로고    scopus 로고
    • Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease
    • Engelhard M, Unterhalt M, Hansmann M et al. Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease. Ann Oncol 2008; 19 (suppl. 4): 418.
    • (2008) Ann Oncol , vol.19 , pp. 418
    • Engelhard, M.1    Unterhalt, M.2    Hansmann, M.3
  • 12
    • 34249704600 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    • Schulz H, Bohlius JF, Trelle S et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 706-714
    • Schulz, H.1    Bohlius, J.F.2    Trelle, S.3
  • 13
    • 20144376591 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
    • Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
    • (2005) J Clin Oncol , vol.23 , pp. 1984-1992
    • Lenz, G.1    Dreyling, M.2    Hoster, E.3
  • 14
    • 61449265721 scopus 로고    scopus 로고
    • Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone-50 months update of the OSHO phase III study (OSHO#39)
    • abstr 12
    • Herold M, Haas A, Doerken B et al. Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone-50 months update of the OSHO phase III study (OSHO#39). Ann Oncol 2008; 19: abstr 12.
    • (2008) Ann Oncol , vol.19
    • Herold, M.1    Haas, A.2    Doerken, B.3
  • 15
    • 77956046528 scopus 로고    scopus 로고
    • Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
    • Gressin R, Caulet-Maugendre S, Deconinck E et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010; 95: 1350-1357.
    • (2010) Haematologica , vol.95 , pp. 1350-1357
    • Gressin, R.1    Caulet-Maugendre, S.2    Deconinck, E.3
  • 16
    • 79951718283 scopus 로고    scopus 로고
    • Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
    • Sachanas S, Pangalis GA, Vassilakopoulos TP et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma 2011; 52: 387-393.
    • (2011) Leuk Lymphoma , vol.52 , pp. 387-393
    • Sachanas, S.1    Pangalis, G.A.2    Vassilakopoulos, T.P.3
  • 17
    • 84864715966 scopus 로고    scopus 로고
    • Treatment of older patients with mantle-cell lymphoma
    • Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
    • (2012) N Engl J Med , vol.367 , pp. 520-531
    • Kluin-Nelemans, H.C.1    Hoster, E.2    Hermine, O.3
  • 18
    • 84875840492 scopus 로고    scopus 로고
    • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantlecell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
    • Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantlecell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
    • (2013) Lancet , vol.381 , pp. 1203-1210
    • Rummel, M.J.1    Niederle, N.2    Maschmeyer, G.3
  • 19
    • 84900423736 scopus 로고    scopus 로고
    • Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
    • Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
    • (2014) Blood , vol.123 , pp. 2944-2952
    • Flinn, I.W.1    van der Jagt, R.2    Kahl, B.S.3
  • 20
    • 20044381673 scopus 로고    scopus 로고
    • Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
    • Ghielmini M, Schmitz SF, Cogliatti S et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705-711.
    • (2005) J Clin Oncol , vol.23 , pp. 705-711
    • Ghielmini, M.1    Schmitz, S.F.2    Cogliatti, S.3
  • 21
    • 84884755581 scopus 로고    scopus 로고
    • Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B
    • Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765- 2772.
    • (2013) J Clin Oncol , vol.31 , pp. 2765- 2772
    • Huang, Y.H.1    Hsiao, L.T.2    Hong, Y.C.3
  • 22
    • 84865765565 scopus 로고    scopus 로고
    • Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
    • Smith MR, Li H, Gordon L et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119-3126.
    • (2012) J Clin Oncol , vol.30 , pp. 3119-3126
    • Smith, M.R.1    Li, H.2    Gordon, L.3
  • 23
    • 20144388941 scopus 로고    scopus 로고
    • Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
    • Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
    • (2005) Blood , vol.105 , pp. 2677-2684
    • Dreyling, M.1    Lenz, G.2    Hoster, E.3
  • 24
    • 77953045695 scopus 로고    scopus 로고
    • Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma
    • Hoster E, Metzner B, Forstpointner R et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114: 880.
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114 , pp. 880
    • Hoster, E.1    Metzner, B.2    Forstpointner, R.3
  • 25
    • 84883133544 scopus 로고    scopus 로고
    • Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma
    • Final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
    • Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.
    • (2012) Blood (ASH Annual Meeting Abstracts) , vol.120 , pp. 151
    • Hermine, O.1    Hoster, E.2    Walewski, J.3
  • 26
    • 74949115388 scopus 로고    scopus 로고
    • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
    • Damon LE, Johnson JL, Niedzwiecki D et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101-6108.
    • (2009) J Clin Oncol , vol.27 , pp. 6101-6108
    • Damon, L.E.1    Johnson, J.L.2    Niedzwiecki, D.3
  • 27
    • 58549085393 scopus 로고    scopus 로고
    • High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
    • van 't Veer MB, de Jong D, MacKenzie M et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144: 524-530.
    • (2009) Br J Haematol , vol.144 , pp. 524-530
    • Van't Veer, M.B.1    De Jong, D.2    MacKenzie, M.3
  • 28
    • 84863822702 scopus 로고    scopus 로고
    • Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
    • Geisler CH, Kolstad A, Laurell A et al. Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
    • (2012) Br J Haematol , vol.158 , pp. 355-362
    • Geisler, C.H.1    Kolstad, A.2    Laurell, A.3
  • 29
    • 84872054301 scopus 로고    scopus 로고
    • CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
    • Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
    • (2013) Blood , vol.121 , pp. 48-53
    • Delarue, R.1    Haioun, C.2    Ribrag, V.3
  • 30
    • 84895061381 scopus 로고    scopus 로고
    • Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC
    • Touzeau C, Leux C, Bouabdallah R et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014; 93: 233-242.
    • (2014) Ann Hematol , vol.93 , pp. 233-242
    • Touzeau, C.1    Leux, C.2    Bouabdallah, R.3
  • 31
    • 27244452464 scopus 로고    scopus 로고
    • High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    • Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
    • (2005) J Clin Oncol , vol.23 , pp. 7013-7023
    • Romaguera, J.E.1    Fayad, L.2    Rodriguez, M.A.3
  • 32
    • 84855796484 scopus 로고    scopus 로고
    • Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
    • Merli F, Luminari S, Ilariucci F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346-353.
    • (2012) Br J Haematol , vol.156 , pp. 346-353
    • Merli, F.1    Luminari, S.2    Ilariucci, F.3
  • 33
    • 84878457954 scopus 로고    scopus 로고
    • A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
    • Bernstein SH, Epner E, Unger JM et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24: 1587-1593.
    • (2013) Ann Oncol , vol.24 , pp. 1587-1593
    • Bernstein, S.H.1    Epner, E.2    Unger, J.M.3
  • 34
    • 84899755490 scopus 로고    scopus 로고
    • High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
    • Laurell A, Kolstad A, Jerkeman M et al. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. Leuk Lymphoma 2014; 55: 1206-1208.
    • (2014) Leuk Lymphoma , vol.55 , pp. 1206-1208
    • Laurell, A.1    Kolstad, A.2    Jerkeman, M.3
  • 35
    • 84911497441 scopus 로고    scopus 로고
    • Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma-a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials
    • Hoster E, Geisler GH, Doorduijn JK et al. Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma-a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood (ASH Annual Meeting Abstracts) 2013; 122: 3367.
    • (2013) Blood (ASH Annual Meeting Abstracts) , vol.122 , pp. 3367
    • Hoster, E.1    Geisler, G.H.2    Doorduijn, J.K.3
  • 36
    • 84883220460 scopus 로고    scopus 로고
    • Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study
    • Le Gouill S, Callanan M, Macintyre E et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 152.
    • (2012) Blood (ASH Annual Meeting Abstracts) , vol.120 , pp. 152
    • Le Gouill, S.1    Callanan, M.2    Macintyre, E.3
  • 37
    • 84905575740 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
    • Krüger WH, Hirt C, Basara N et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol 2014; 93: 1587-1597.
    • (2014) Ann Hematol , vol.93 , pp. 1587-1597
    • Krüger, W.H.1    Hirt, C.2    Basara, N.3
  • 38
    • 84875606235 scopus 로고    scopus 로고
    • Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
    • Visco C, Finotto S, Zambello R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-1449.
    • (2013) J Clin Oncol , vol.31 , pp. 1442-1449
    • Visco, C.1    Finotto, S.2    Zambello, R.3
  • 39
    • 68949102180 scopus 로고    scopus 로고
    • Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    • Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
    • (2009) J Clin Oncol , vol.27 , pp. 3822-3829
    • Hess, G.1    Herbrecht, R.2    Romaguera, J.3
  • 40
    • 61649094981 scopus 로고    scopus 로고
    • Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
    • Goy A, Bernstein SH, Kahl BS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520-525.
    • (2009) Ann Oncol , vol.20 , pp. 520-525
    • Goy, A.1    Bernstein, S.H.2    Kahl, B.S.3
  • 41
    • 84887030194 scopus 로고    scopus 로고
    • Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
    • Zinzani PL, Vose JM, Czuczman MS et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892-2897.
    • (2013) Ann Oncol , vol.24 , pp. 2892-2897
    • Zinzani, P.L.1    Vose, J.M.2    Czuczman, M.S.3
  • 42
    • 84881225049 scopus 로고    scopus 로고
    • Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    • Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
    • (2013) N Engl J Med , vol.369 , pp. 507-516
    • Wang, M.L.1    Rule, S.2    Martin, P.3
  • 43
    • 79959923820 scopus 로고    scopus 로고
    • Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapyrefractory mantle cell lymphoma
    • Lamm W, Kaufmann H, Raderer M et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapyrefractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014.
    • (2011) Haematologica , vol.96 , pp. 1008-1014
    • Lamm, W.1    Kaufmann, H.2    Raderer, M.3
  • 44
    • 79951700533 scopus 로고    scopus 로고
    • A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
    • Kouroukis CT, Fernandez LA, Crump M et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 2011; 52: 394-399.
    • (2011) Leuk Lymphoma , vol.52 , pp. 394-399
    • Kouroukis, C.T.1    Fernandez, L.A.2    Crump, M.3
  • 45
    • 23944481410 scopus 로고    scopus 로고
    • Phase II trial of single-agent temsirolimus (CCI- 779) for relapsed mantle cell lymphoma
    • Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI- 779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
    • (2005) J Clin Oncol , vol.23 , pp. 5347-5356
    • Witzig, T.E.1    Geyer, S.M.2    Ghobrial, I.3
  • 46
    • 49049087320 scopus 로고    scopus 로고
    • Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
    • Ansell SM, Inwards DJ, Rowland KM, Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508-514.
    • (2008) Cancer , vol.113 , pp. 508-514
    • Ansell, S.M.1    Inwards, D.J.2    Rowland Jr, K.M.3
  • 47
    • 79953182631 scopus 로고    scopus 로고
    • Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    • Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368.
    • (2011) Lancet Oncol , vol.12 , pp. 361-368
    • Ansell, S.M.1    Tang, H.2    Kurtin, P.J.3
  • 48
    • 84863971730 scopus 로고    scopus 로고
    • A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
    • Renner C, Zinzani PL, Gressin R et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085-1091.
    • (2012) Haematologica , vol.97 , pp. 1085-1091
    • Renner, C.1    Zinzani, P.L.2    Gressin, R.3
  • 49
    • 84889099537 scopus 로고    scopus 로고
    • Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
    • Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
    • (2013) J Clin Oncol , vol.31 , pp. 3688-3695
    • Goy, A.1    Sinha, R.2    Williams, M.E.3
  • 50
    • 84863107308 scopus 로고    scopus 로고
    • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    • Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
    • (2012) Lancet Oncol , vol.13 , pp. 716-723
    • Wang, M.1    Fayad, L.2    Wagner-Bartak, N.3
  • 51
    • 84857740069 scopus 로고    scopus 로고
    • Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
    • Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
    • (2012) Haematologica , vol.97 , pp. 416-422
    • Zaja, F.1    De Luca, S.2    Vitolo, U.3
  • 52
    • 79960490364 scopus 로고    scopus 로고
    • Treatment of younger patients with mantle cell lymphoma
    • Harel S, Delarue R, Ribrag V et al. Treatment of younger patients with mantle cell lymphoma. Semin Hematol 2011; 48: 194-207.
    • (2011) Semin Hematol , vol.48 , pp. 194-207
    • Harel, S.1    Delarue, R.2    Ribrag, V.3
  • 53
    • 77952839682 scopus 로고    scopus 로고
    • Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
    • Ruan J, Martin P, Coleman M et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116: 2655-2664.
    • (2010) Cancer , vol.116 , pp. 2655-2664
    • Ruan, J.1    Martin, P.2    Coleman, M.3
  • 54
    • 70449727887 scopus 로고    scopus 로고
    • Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
    • Wang M, Oki Y, Pro B et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213-5218.
    • (2009) J Clin Oncol , vol.27 , pp. 5213-5218
    • Wang, M.1    Oki, Y.2    Pro, B.3
  • 55
    • 84911487354 scopus 로고    scopus 로고
    • Radioimmunotherapy in relapsed/ refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial
    • Ferrero S, Pastore A, Forstpointner R et al. Radioimmunotherapy in relapsed/ refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial. Blood (ASH Annual Meeting Abstracts) 2013; 122: 4384.
    • (2013) Blood (ASH Annual Meeting Abstracts) , vol.122 , pp. 4384
    • Ferrero, S.1    Pastore, A.2    Forstpointner, R.3
  • 56
    • 84891442057 scopus 로고    scopus 로고
    • Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
    • Morschhauser FA, Cartron G, Thieblemont C et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919.
    • (2013) J Clin Oncol , vol.31 , pp. 2912-2919
    • Morschhauser, F.A.1    Cartron, G.2    Thieblemont, C.3
  • 57
    • 84901724050 scopus 로고    scopus 로고
    • A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
    • Kahl BS, Spurgeon SE, Furman RR et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.
    • (2014) Blood , vol.123 , pp. 3398-3405
    • Kahl, B.S.1    Spurgeon, S.E.2    Furman, R.R.3
  • 58
    • 84902254046 scopus 로고    scopus 로고
    • The single-agent Bcl-2 inhibitor ABT- 199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients
    • Davids MS, Seymour JF, Gerecitano JF et al. The single-agent Bcl-2 inhibitor ABT- 199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood (ASH Annual Meeting Abstracts) 2013; 122: 1789.
    • (2013) Blood (ASH Annual Meeting Abstracts) , vol.122 , pp. 1789
    • Davids, M.S.1    Seymour, J.F.2    Gerecitano, J.F.3
  • 59
    • 33845515497 scopus 로고    scopus 로고
    • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
    • Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
    • (2006) Blood , vol.108 , pp. 4003-4008
    • Forstpointner, R.1    Unterhalt, M.2    Dreyling, M.3
  • 60
    • 84882746664 scopus 로고    scopus 로고
    • Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    • Cassaday RD, Guthrie KA, Budde EL et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1403-1406.
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 1403-1406
    • Cassaday, R.D.1    Guthrie, K.A.2    Budde, E.L.3
  • 61
    • 85027906668 scopus 로고    scopus 로고
    • The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
    • Jul 18 [Epub ahead of print]
    • Robinson S, Dreger P, Caballero D et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2014; Jul 18 [Epub ahead of print].
    • (2014) Leukemia
    • Robinson, S.1    Dreger, P.2    Caballero, D.3
  • 62
    • 84903462466 scopus 로고    scopus 로고
    • Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma-the Lugano Classification
    • in press
    • Cheson B, Fisher R, Barrington S et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma-the Lugano Classification. JCO 2014; in press.
    • (2014) JCO
    • Cheson, B.1    Fisher, R.2    Barrington, S.3
  • 63
    • 77951453410 scopus 로고    scopus 로고
    • Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
    • Pott C, Hoster E, Delfau-Larue MH et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215-3223.
    • (2010) Blood , vol.115 , pp. 3215-3223
    • Pott, C.1    Hoster, E.2    Delfau-Larue, M.H.3
  • 64
    • 33845249942 scopus 로고    scopus 로고
    • Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
    • Ladetto M, Magni M, Pagliano G et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270-1276.
    • (2006) Biol Blood Marrow Transplant , vol.12 , pp. 1270-1276
    • Ladetto, M.1    Magni, M.2    Pagliano, G.3
  • 65
    • 0035879607 scopus 로고    scopus 로고
    • Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
    • Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
    • (2001) Clin Infect Dis , vol.33 , pp. 139-144
    • Dykewicz, C.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.